Ra Pharmaceuticals Inc (RARX) Return on Assets ROA from the fourth quarter of 2019 to fourth quarter of 2018 and for the year 2019, Average High and Low, Fundamental Ratios from Dec 31 2019 to Dec 31 2018 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Ra Pharmaceuticals Inc   (RARX)


Ra Pharmaceuticals Inc 's ROA from the fourth quarter of 2019 to the fourth quarter of 2018 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Ra Pharmaceuticals Inc 's ROA in the fourth quarter of 2019?
Ra Pharmaceuticals Inc recorded a cumulative net loss of $-103 million during 12 months ending in the fourth quarter of 2019, resulting in a negative return on assets (ROA) of -41.66%.

However, within the Healthcare sector 524 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2019 from 4097 to 4636.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Dec 31 2019)
IV. Quarter		 (Sep 30 2019)
III. Quarter		 (Jun 30 2019)
II. Quarter		 (Mar 31 2019)
I. Quarter		 (Dec 31 2018)
IV. Quarter
Y / Y Total Assets Change 28.98 % 240.92 % 79.31 % 73.53 % 173.35 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -103 -82 -74 -67 -65
Return On Assets (TTM) -41.66 % -35.6 % -41.83 % -43.51 % -48.69 %
RARX's Total Ranking # 4636 # 4097 # 4221 # 4292 # 4822
Total Assets (TTM) in million 283 309 189 205 219
Seq. Total Assets Change -8.47 % 63.25 % -7.72 % -6.46 % 141.91 %
Seq. Net Income Change - - - - -

RARX's 5 Years Annual ROA >> Back to RARX Management Effectiveness >> Compare RARX ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 226
Sector # 525
Overall # 4476

Return On Assets Statistics
High Average Low
-35.6 %
-49.18 %
-64.77 %
(Sep 30 2019)   (Sep 30 2018)





Financial Statements
Ra Pharmaceuticals Inc 's Assets $ 283 million RARX's Balance sheet
Ra Pharmaceuticals Inc 's Income $ -37 million Quarterly RARX's Income Statement
RARX's Income by Division See RARX's Income by Division



Annual Return On Assets (Dec 31 2019)
FY 2019		 (Dec 31 2018)
FY 2018		 (Dec 31 2017)
FY 2017		 (Dec 31 2014)
FY 2016
FY
Y / Y Total Assets Change 29.62 % 173.35 % 85.73 % - -
Total Assets in million 284 219 80 43 0
Y / Y Net Income Change - - - - -
Net Income in million -103 -65 -54 -5 0
Annual Return On Assets -36.14 % -29.62 % -67.88 % -12.68 % -

RARX's 5 Years Annual ROA >> Back to RARX Management Effectiveness >> Compare RARX ROA to its Competitors



More Return On Assets Ratios
RARX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
RARX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for RARX's Competitors
Subscribers only: Roa for Ra Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for RARX's Customers

You may also want to know
RARX's Roi RARX's Inventory Turnover Ratio RARX's Growth Rates RARX's Dividend Comparisons
RARX's Profitability Ratios RARX's Asset Turnover Ratio RARX's Dividend Growth
RARX's Roe RARX's Valuation Ratios RARX's Financial Strength Ratios RARX's Dividend Payout Ratio



Companies with similar Return On Assets at Dec 31 2019, within Healthcare Sector ROA

Date modified: 2026-09-18T13:11:04+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.